Research programme: apoptosis inducers - EpiCept Corporation

Drug Profile

Research programme: apoptosis inducers - EpiCept Corporation

Alternative Names: CV 2116; CV 43468; CV 55510; CV 58211; EP128504; EP129168; EP2161; EP95615; EPC 2167; Gambogic acid; MX 128504; MX 2060; MX 2167; MX 59003; MX 63844; MX 69501; MX 72086; MX 73883; MX 73936; MX 74420; MX 76629; MX 77356

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EpiCept Corporation
  • Developer Immune Pharmaceuticals Inc
  • Class Fluorenes; Nicotinic-acids; Pyrimidines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Caspase stimulants; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
  • 20 Aug 2013 EpiCept Corporation has been acquired by Immune Pharmaceuticals Ltd
  • 26 Mar 2009 In vitro data presented at the 237th American Chemical Society National Meeting (ACS-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top